<DOC>
	<DOCNO>NCT01102413</DOCNO>
	<brief_summary>The study design determine effect investigational drug Monofer subject non-dialysis dependent chronic kidney disease ( NDD-CKD ) subject iron deficiency anaemia ( IDA ) .</brief_summary>
	<brief_title>Iron Isomaltoside 1000 ( Monofer® ) Non-Dialysis Dependent Chronic Kidney Disease With Renal-Related Anaemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Men woman , age 18 year . 2 . Subjects diagnose NDDCKD MDRD calculate eGFR 1559 mL/min . 3 . Hb &lt; 11.0 g/dL ( 6.80 mmol/L ) 4 . Either follow iron store indicator target { Serum ferritin &lt; 100 ug/l Transferrin saturation ( TfS ) &lt; 20 % } . 5 . Life expectancy beyond 12 month Principal Investigator 's judgement . 6 . Willingness participate inform consent authorization require local law ( e.g . Protected Health Information [ PHI ] North America ) . 1 . Anaemia predominantly cause factor renal impairment iron deficiency ( accord Principal Investigator 's judgment ) . 2 . Iron overload disturbance utilisation iron ( e.g . haemochromatosis haemosiderosis ) . 3 . Drug hypersensitivity ( i.e . previous hypersensitivity Iron Dextran iron mono disaccharide complex iron sulphate excipients study drug . 4 . Subjects history multiple allergy . 5 . Decompensated liver cirrhosis active hepatitis ( Alanine Aminotransferase ( ALT ) &gt; 3 time upper normal limit ) . 6 . Active acute chronic infection ( ( assess clinical judgment ) , supply White Blood Cells ( WBC ) CReactive Protein ( CRP ) ) . 7 . Rheumatoid arthritis symptom sign active joint inflammation . 8 . Pregnancy nursing ( To avoid pregnancy , woman postmenopausal ( least 12 month must elapse since last menstruation ) , surgically sterile , woman child bear potential must use one follow contraceptive whole study period study end least 5 time plasma biological halflife investigational medicinal product ( 5 day ) : Contraceptive pill , intrauterine device ( IUD ) , contraceptive depot injection ( prolongedrelease gestagen ) , subdermal implantation , vaginal ring , transdermal patch ) . 9 . Extensive active bleeding necessitate blood transfusion . 10 . Planned elective surgery study . 11 . Participation clinical study within 3 month prior screen . 12 . Known intolerance oral iron treatment . 13 . Untreated B12 folate deficiency . 14 . I.V . oral iron treatment blood transfusion within 4 week prior screen visit . 15 . ESA treatment within 8 week prior screen visit . 16 . Serum ferritin &gt; 500 µg/L . 17 . Any medical condition , opinion Principal Investigator , may cause subject unsuitable completion study place subject potential risk study interfere study drug evaluation . Example , Uncontrolled Hypertension , Unstable Ischemic Heart Disease Uncontrolled Diabetes Mellitus . 18 . Body weight &lt; 30 kilogram .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>